Literature DB >> 8822917

A severe and consistent deficit in marrow and circulating primitive hematopoietic cells (long-term culture-initiating cells) in acquired aplastic anemia.

J P Maciejewski1, C Selleri, T Sato, S Anderson, N S Young.   

Abstract

We examined the stem cell compartment of patients with acquired aplastic anemia (AA) using the long-term culture-initiating cell assay (LTC-IC), in parallel with measurements of CD34+ cells and mature hematopoietic progenitors. Secondary colonies from cells surviving 5 weeks of long-term bone marrow culture (LTBMC) were determined for the peripheral blood (PB) of 68 AA patients and 13 normal controls and for BM of 49 AA patients and 14 controls; because of low cell numbers, formal limiting dilution analysis could only be performed in 10 patients. The relationship of cell input in LTBMC and the output of secondary colonies was linear, allowing quantification of LTC-IC number from bulk cultures. Secondary colony formation was markedly abnormal in severe AA. In contrast to 7.8 colony-forming cells (CFC)/10(5) mononuclear cells in normal BM and 0.14 CFC/10(5) normal PB mononuclear cells, patients with severe disease showed 0.024 CFC/10(5) in BM and 0.0068 CFC/10(5) in PB. Under limiting dilution conditions, patients' cells also showed markedly lower colony-forming ability. In contrast to 4.3 +/- 1 colonies/normal LTC-IC, we obtained only 1.27 +/- 0.09 and 2.0 +/- 0.35 colonies from BM of acute and recovered cases, respectively. These values were used to extrapolate LTC-IC numbers from secondary colony formation in suspension cultures. In PB, calculated LTC-IC were decreased 7.4-fold in new and relapsed severe AA and 2.8-fold in recovered AA. In BM, LTC-IC were decreased 10-fold in new and relapsed AA and sixfold in recovered cases. Compared with measurements obtained on presentation, LTC-IC were lower in post-treatment samples from patients who had failed to recover after intensive immunosuppression and relatively higher in cases at relapse. In recovered patients, LTC-IC number increased but remained below the normal range in 20 of 25. In patients studied serially for 3 to 12 months after treatment, LTC-IC numbers remained stable but low. LTC-IC number correlated with concurrently determined CD34+ cell number and primary hematopoietic colony formation. These results indicate that stem cell numbers, as quantitated by the LTC-IC assay, are markedly diminished in number in all severe AA. Additionally, the function of the stem cell or the stem cell compartment in AA is also abnormal, as inferred from the low clonogenic potential in secondary colony assays. Early hematologic improvement in some patients occurs without increasing numbers of LTC-IC, and a minority of recovered cases show apparent repopulation of the LTC-IC compartment years after treatment.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8822917

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  34 in total

Review 1.  Drug-induced myelosuppression : diagnosis and management.

Authors:  Peter J Carey
Journal:  Drug Saf       Date:  2003       Impact factor: 5.606

2.  Eltrombopag restores trilineage hematopoiesis in refractory severe aplastic anemia that can be sustained on discontinuation of drug.

Authors:  Ronan Desmond; Danielle M Townsley; Bogdan Dumitriu; Matthew J Olnes; Phillip Scheinberg; Margaret Bevans; Ankur R Parikh; Kinneret Broder; Katherine R Calvo; Colin O Wu; Neal S Young; Cynthia E Dunbar
Journal:  Blood       Date:  2013-12-17       Impact factor: 22.113

3.  Eltrombopag Added to Standard Immunosuppression for Aplastic Anemia.

Authors:  Danielle M Townsley; Phillip Scheinberg; Thomas Winkler; Ronan Desmond; Bogdan Dumitriu; Olga Rios; Barbara Weinstein; Janet Valdez; Jennifer Lotter; Xingmin Feng; Marie Desierto; Harshraj Leuva; Margaret Bevans; Colin Wu; Andre Larochelle; Katherine R Calvo; Cynthia E Dunbar; Neal S Young
Journal:  N Engl J Med       Date:  2017-04-20       Impact factor: 91.245

4.  Alterations in hematopoietic microenvironment in patients with aplastic anemia.

Authors:  Irina N Shipounova; Tatiana V Petrova; Daria A Svinareva; Kira S Momotuk; Elena A Mikhailova; Nina I Drize
Journal:  Clin Transl Sci       Date:  2009-02       Impact factor: 4.689

5.  Evaluation of treatment responses and colony-forming progenitor cells in 50 patients with aplastic anemia after immunosuppressive therapy or hematopoietic stem cell transplantation: a single-center experience.

Authors:  Wolfgang Füreder; Andrea Paulitsch-Buckingham; Werner Rabitsch; Eva Jäger; Ilse Schwarzinger; Wolfgang R Sperr; Peter Valent
Journal:  Wien Klin Wochenschr       Date:  2014-01-18       Impact factor: 1.704

Review 6.  Current concepts in the pathophysiology and treatment of aplastic anemia.

Authors:  Neal S Young; Rodrigo T Calado; Phillip Scheinberg
Journal:  Blood       Date:  2006-06-15       Impact factor: 22.113

7.  Interferon-gamma-induced gene expression in CD34 cells: identification of pathologic cytokine-specific signature profiles.

Authors:  Weihua Zeng; Akira Miyazato; Guibin Chen; Sachiko Kajigaya; Neal S Young; Jaroslaw P Maciejewski
Journal:  Blood       Date:  2005-08-30       Impact factor: 22.113

Review 8.  Immune pathophysiology of aplastic anemia.

Authors:  Jaroslaw P Maciejewski; Antonio Risitano; Hoon Kook; Weihua Zeng; Guibin Chen; Neal S Young
Journal:  Int J Hematol       Date:  2002-08       Impact factor: 2.490

9.  Evaluation of Bone Marrow Microvessel Density in Patients with Aplastic Anemia.

Authors:  Venkatesan Somasundaram; Manvir Singh Tevatia; Abhishek Purohit; Ankur Ahuja; Manoranjan Mahapatra; Seema Tyagi; Haraprasad Pati; Renu Saxena
Journal:  Indian J Hematol Blood Transfus       Date:  2016-07-19       Impact factor: 0.900

10.  Alteration in marrow stromal microenvironment and apoptosis mechanisms involved in aplastic anemia: an animal model to study the possible disease pathology.

Authors:  Sumanta Chatterjee; Ranjan Kumar Dutta; Pratima Basak; Prosun Das; Madhurima Das; Jacintha Archana Pereira; Malay Chaklader; Samaresh Chaudhuri; Sujata Law
Journal:  Stem Cells Int       Date:  2010-09-19       Impact factor: 5.443

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.